| Name | Title | Contact Details |
|---|
For over 18 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programmes, and source comparator drugs for clinical trials and bioanalysis. By partnering with Tanner Pharma, manufacturers are able to focus on their primary markets and strategies while ensuring that the services they need will follow a strictly controlled protocol of quality. Headquartered in the U.S. with offices in London, São Paulo and Mexico City, Tanner Pharma Group`s reach includes Europe, Asia, the Middle East, Australia, Canada and Latin America. We measure our value as a company based on the lives we help to improve. For all of us involved in the pharmaceutical supply chain - manufacturers, distributors, pharmacists, doctors, and others - it is ultimately the patient that matters most. Therefore, we start each day with a renewed commitment to ethically supply unlicensed medicines to markets where access continues being a challenge.
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.
Auburn Pharmaceutical is a national full line generics wholesaler that purchases all of its products directly from 100+ manufacturers and is licensed across the Continental United States.
Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo`s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,400 people worldwide*.